Cardiovascular Atlas
About
Menu

Timeline

Dated events in the published records, newest first: regulatory decisions, guideline recommendations and editions, study dates from their registries and milestones that happened. Each date is shown as precisely as its record states it.

208 events. A year or a month is never shown as a day, and a year-only date sorts below the dated events of that year. 19 are registry dates that the registry does not mark as reached, so each says so. Expected future events are on the calendar.

2026 3

  1. Edition published 2026 ESC heart failure guidelines

    Issued by: European Society of Cardiology · Edition: 2026 guidelines

    Source: 2026 ESC Guidelines for the management of heart failure

  2. Results first posted SURPASS-CVOT: tirzepatide against dulaglutide on major cardiovascular events

    Source: A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

  3. Edition published 2026 ACC/AHA multisociety guideline on the management of dyslipidemia

    Issued jointly by: American College of Cardiology, American Heart Association · Edition: 2026 guideline

    Source: 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

2025 7

  1. Edition published 2025 ESC/EACTS valvular heart disease guidelines

    Issued by: European Society of Cardiology · Edition: 2025 guidelines

    Source: 2025 ESC/EACTS Guidelines for the management of valvular heart disease

  2. Study completion SURPASS-CVOT: tirzepatide against dulaglutide on major cardiovascular events

    Source: A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

  3. Primary completion SURPASS-CVOT: tirzepatide against dulaglutide on major cardiovascular events

    Source: A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

  4. Results first posted SECURE

    Source: Secondary Prevention of Cardiovascular Disease in the Elderly Trial

  5. Results first posted FLOW: semaglutide and kidney outcomes in type 2 diabetes with chronic kidney disease

    Source: A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

  6. Edition published Use of lower-sodium salt substitutes: WHO guideline (2025)

    Issued by: World Health Organization · Edition: WHO guideline, 2025. The WHO page dates it 27 January 2025 and the PDF title page shows only the year.

    Source: Use of lower-sodium salt substitutes: WHO guideline

  7. Recommended Salt substitution (lower-sodium, potassium-containing salt)

    Issued by: World Health Organization · Where: Global · Strength: Conditional recommendation

    Source: Use of lower-sodium salt substitutes: WHO guideline

2024 9

  1. Edition published 2024 ESC atrial fibrillation guidelines

    Issued by: European Society of Cardiology · Edition: 2024 guidelines

    Source: 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)

  2. Results first posted SELECT: semaglutide and cardiovascular outcomes in overweight or obesity

    Source: Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

  3. Study completion EMPA-KIDNEY: empagliflozin in a broad range of chronic kidney disease

    Source: EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

  4. Approval TriClip

    Authority: U.S. Food and Drug Administration · Pathway: PMA · Submission: P230007 · Where: United States

    Source: FDA premarket approval record P230007: TriClip G4 System (original PMA approval) (openFDA record)

  5. Primary completion EARLY TAVR

    Source: EARLY TAVR: Evaluation of TAVR Compared to Surveillance for Patients With Asymptomatic Severe Aortic Stenosis

  6. Results first posted TRILUMINATE Pivotal trial

    Source: TRILUMINATE Pivotal Trial

  7. Study completion FLOW: semaglutide and kidney outcomes in type 2 diabetes with chronic kidney disease

    Source: A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

  8. Primary completion FLOW: semaglutide and kidney outcomes in type 2 diabetes with chronic kidney disease

    Source: A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

  9. Results first posted CLEAR Outcomes (bempedoic acid in statin-intolerant people)

    Source: Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo

2023 7

  1. Edition published 2023 ACC/AHA/ACCP/HRS atrial fibrillation guideline

    Issued jointly by: American College of Cardiology, American Heart Association, American College of Clinical Pharmacy · Edition: 2023 guideline

    Source: 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

  2. Results first posted Look AHEAD: intensive lifestyle intervention in type 2 diabetes

    Source: Look AHEAD: Action for Health in Diabetes

  3. Results first posted EMPA-KIDNEY: empagliflozin in a broad range of chronic kidney disease

    Source: EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

  4. Results first posted DELIVER

    Source: Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.

  5. Study completion SELECT: semaglutide and cardiovascular outcomes in overweight or obesity

    Source: Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

  6. Primary completion SELECT: semaglutide and cardiovascular outcomes in overweight or obesity

    Source: Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

  7. Study completion ISCHEMIA (initial invasive or conservative strategy for stable coronary disease)

    Source: International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)

2022 22

  1. Study completion TTM2

    Source: Targeted Hypothermia Versus Targeted Normothermia After Out-of-hospital Cardiac Arrest

  2. Edition published ADA/KDIGO 2022 consensus report on diabetes management in CKD

    Issued jointly by: American Diabetes Association, Kidney Disease: Improving Global Outcomes (KDIGO) · Edition: 2022 consensus report

    Source: Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)

  3. Recommended Finerenone

    Issued by: Kidney Disease: Improving Global Outcomes (KDIGO) · Where: Not stated · Strength: Consensus statement; the report prints no class of recommendation

    Source: Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)

  4. Primary completion TRILUMINATE Pivotal trial

    Source: TRILUMINATE Pivotal Trial

  5. Study completion CLEAR Outcomes (bempedoic acid in statin-intolerant people)

    Source: Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo

  6. Primary completion CLEAR Outcomes (bempedoic acid in statin-intolerant people)

    Source: Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo

  7. Edition published USPSTF 2022: statin use for primary prevention of CVD in adults

    Issued by: U.S. Preventive Services Task Force · Edition: 2022 recommendation statement

    Source: Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement

  8. Evidence is insufficient to recommend for or against Statins

    Issued by: U.S. Preventive Services Task Force · Where: United States · Strength: I statement (evidence insufficient)

    Source: Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement

  9. Recommended Statins

    Issued by: U.S. Preventive Services Task Force · Where: United States · Strength: B recommendation

    Source: Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement

  10. Study completion WHO HEARTS evaluation in Bangladesh

    Source: HEARTS Package Evaluation Trial in Bangladesh

  11. Primary completion EMPA-KIDNEY: empagliflozin in a broad range of chronic kidney disease

    Source: EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

  12. Primary completion TTM2

    Source: Targeted Hypothermia Versus Targeted Normothermia After Out-of-hospital Cardiac Arrest

  13. Results first posted EMPEROR-Preserved

    Source: EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)

  14. Approval Tirzepatide (Mounjaro)

    Authority: U.S. Food and Drug Administration · Pathway: NDA · Submission: NDA215866 · Where: United States

    Sources: FDA New Drug Application NDA215866: Mounjaro (openFDA drugsfda record); Drugs@FDA: approval date(s) and history for NDA 215866 (Mounjaro); Mounjaro drug label (openFDA record, set id d2d7da5d-ad07-4228-955f-cf7e355c8cc0)

  15. Edition published USPSTF 2022: aspirin use to prevent CVD

    Issued by: U.S. Preventive Services Task Force · Edition: 2022 recommendation statement

    Source: Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement

  16. Recommended against Aspirin

    Issued by: U.S. Preventive Services Task Force · Where: United States · Strength: D recommendation

    Source: Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement

  17. Edition published 2022 AHA/ACC/HFSA heart failure guideline

    Issued jointly by: American Heart Association, American College of Cardiology · Edition: 2022 guideline

    Source: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

  18. Recommended SGLT2 inhibitors (drug class)

    Issued by: American College of Cardiology · Where: Not stated · Strength: Class of Recommendation 1a, as printed on the ACC summary page

    Source: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

  19. Study completion SECURE

    Source: Secondary Prevention of Cardiovascular Disease in the Elderly Trial

  20. Study completion DELIVER

    Source: Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.

  21. Primary completion DELIVER

    Source: Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.

  22. Edition published USPSTF 2022: screening for atrial fibrillation

    Issued by: U.S. Preventive Services Task Force · Edition: 2022 recommendation statement

    Source: Screening for Atrial Fibrillation: US Preventive Services Task Force Recommendation Statement

2021 24

  1. Primary completion WHO HEARTS evaluation in Bangladesh

    Source: HEARTS Package Evaluation Trial in Bangladesh

  2. Approval Inclisiran (Leqvio)

    Authority: U.S. Food and Drug Administration · Pathway: NDA · Submission: NDA214012 · Where: United States

    Sources: Drugs@FDA application NDA214012: LEQVIO (inclisiran) (openFDA drugsfda record); Drugs@FDA overview page for NDA214012; LEQVIO drug label (openFDA record, set id 6fc0afca-4513-4c35-b594-6544aee29a44)

  3. Results first posted PARTNER 3 trial

    Source: PARTNER 3 Trial: Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis

  4. Primary completion SECURE

    Source: Secondary Prevention of Cardiovascular Disease in the Elderly Trial

  5. Study start WHO HEARTS evaluation in Bangladesh

    Source: HEARTS Package Evaluation Trial in Bangladesh

  6. Results first posted Evolut Low Risk trial

    Source: Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk Patients

  7. Recommended Blood pressure lowering medicine

    Issued by: World Health Organization · Where: Global · Strength: Strong recommendation, moderate- to high-certainty evidence

    Source: Guideline for the pharmacological treatment of hypertension in adults (World Health Organization, 2021)

  8. Recommended Blood pressure lowering medicine

    Issued by: World Health Organization · Where: Global · Strength: Strong recommendation, moderate- to high-certainty evidence

    Source: Guideline for the pharmacological treatment of hypertension in adults (World Health Organization, 2021)

  9. Recommended Blood pressure lowering medicine

    Issued by: World Health Organization · Where: Global · Strength: Conditional recommendation, moderate- to high-certainty evidence

    Source: Guideline for the pharmacological treatment of hypertension in adults (World Health Organization, 2021)

  10. Recommended Blood pressure lowering medicine

    Issued by: World Health Organization · Where: Global · Strength: Strong recommendation, high-certainty evidence

    Source: Guideline for the pharmacological treatment of hypertension in adults (World Health Organization, 2021)

  11. Recommended Blood pressure lowering medicine

    Issued by: World Health Organization · Where: Global · Strength: Conditional recommendation, moderate-certainty evidence

    Source: Guideline for the pharmacological treatment of hypertension in adults (World Health Organization, 2021)

  12. Recommended Blood-pressure lowering to a target

    Issued by: World Health Organization · Where: Global · Strength: Strong recommendation, moderate-certainty evidence

    Source: Guideline for the pharmacological treatment of hypertension in adults (World Health Organization, 2021)

  13. Recommended Blood-pressure lowering to a target

    Issued by: World Health Organization · Where: Global · Strength: Strong recommendation, moderate-certainty evidence

    Source: Guideline for the pharmacological treatment of hypertension in adults (World Health Organization, 2021)

  14. Recommended Blood-pressure lowering to a target

    Issued by: World Health Organization · Where: Global · Strength: Conditional recommendation, moderate-certainty evidence

    Source: Guideline for the pharmacological treatment of hypertension in adults (World Health Organization, 2021)

  15. Recommended Hypertension treatment by nonphysician professionals, such as pharmacists and nurses

    Issued by: World Health Organization · Where: Global · Strength: Conditional recommendation, low-certainty evidence

    Source: Guideline for the pharmacological treatment of hypertension in adults (World Health Organization, 2021)

  16. Results first posted FIDELIO-DKD: finerenone and kidney outcomes in type 2 diabetes

    Source: Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease

  17. Approval Finerenone (Kerendia)

    Authority: U.S. Food and Drug Administration · Pathway: NDA · Submission: NDA215341 · Where: United States

    Sources: FDA New Drug Application NDA215341: Kerendia (openFDA drugsfda record); Drugs@FDA: approval date(s) and history for NDA 215341 (Kerendia)

  18. Results first posted DAPA-CKD: dapagliflozin in chronic kidney disease

    Source: A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease

  19. Approval Semaglutide injection for weight management (Wegovy)

    Authority: U.S. Food and Drug Administration · Pathway: NDA · Submission: NDA215256 · Where: United States

    Sources: FDA New Drug Application NDA215256: Wegovy (openFDA drugsfda record); Drugs@FDA: approval date(s) and history for NDA 215256 (Wegovy); WEGOVY drug label (openFDA record, set id f5e548d0-cc79-4c34-a3f5-e20a5b8b6564)

  20. Results first posted EMPEROR-Reduced

    Source: EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)

  21. Edition published USPSTF 2021: screening for hypertension in adults

    Issued by: U.S. Preventive Services Task Force · Edition: 2021 reaffirmation statement

    Source: Screening for Hypertension in Adults: US Preventive Services Task Force Reaffirmation Recommendation Statement

  22. Study completion EMPEROR-Preserved

    Source: EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)

  23. Primary completion EMPEROR-Preserved

    Source: EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)

  24. Primary completion Evolut Low Risk trial

    Source: Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk Patients

2020 17

  1. Edition published 2020 ACC/AHA valvular heart disease guideline

    Issued jointly by: American College of Cardiology, American Heart Association · Edition: 2020 guideline

    Source: 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

  2. Recommended Transcatheter aortic valve replacement (TAVR)

    Issued by: American College of Cardiology · Where: Not stated · Strength: Class 1, from the label (all Class 1) that introduces the list of rules, which includes this one

    Source: 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

  3. Primary completion PARTNER 3 trial

    Source: PARTNER 3 Trial: Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis

  4. Study completion China Salt Substitute and Stroke Study (SSaSS)

    Source: China Salt Substitute and Stroke Study

  5. Primary completion China Salt Substitute and Stroke Study (SSaSS)

    Source: China Salt Substitute and Stroke Study

  6. Results first posted DAPA-HF

    Source: Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure

  7. Results first posted ISCHEMIA (initial invasive or conservative strategy for stable coronary disease)

    Source: International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)

  8. Study completion Look AHEAD: intensive lifestyle intervention in type 2 diabetes

    Source: Look AHEAD: Action for Health in Diabetes

  9. Study completion DAPA-CKD: dapagliflozin in chronic kidney disease

    Source: A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease

  10. Primary completion DAPA-CKD: dapagliflozin in chronic kidney disease

    Source: A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease

  11. Study start SURPASS-CVOT: tirzepatide against dulaglutide on major cardiovascular events

    Source: A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

  12. Study completion EMPEROR-Reduced

    Source: EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)

  13. Results first posted COAPT trial

    Source: Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation (The COAPT Trial) and COAPT CAS

  14. Primary completion EMPEROR-Reduced

    Source: EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)

  15. Study completion FIDELIO-DKD: finerenone and kidney outcomes in type 2 diabetes

    Source: Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease

  16. Primary completion FIDELIO-DKD: finerenone and kidney outcomes in type 2 diabetes

    Source: Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease

  17. Results first posted Apple Heart Study Registry does not say if reached

    Source: Apple Heart Study: Assessment of Wristwatch-Based Photoplethysmography to Identify Cardiac Arrhythmias

2019 21

  1. Results first posted DECLARE-TIMI 58: dapagliflozin and cardiovascular outcomes in type 2 diabetes

    Source: Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events

  2. Recommended Ambulatory blood pressure monitoring (ABPM)

    Issued by: National Institute for Health and Care Excellence · Where: GB-ENG (United Kingdom) · Strength: Not labeled on the fetched page. The recommendation uses the verb offer.

    Sources: Hypertension in adults: diagnosis and management (NICE guideline NG136), Recommendations chapter; Making decisions using NICE guidelines; NICE terms and conditions, including the Notice of Rights

  3. Recommended Home blood pressure monitoring

    Issued by: National Institute for Health and Care Excellence · Where: GB-ENG (United Kingdom) · Strength: Not labeled on the fetched page. The recommendation uses the verb offer.

    Sources: Hypertension in adults: diagnosis and management (NICE guideline NG136), Recommendations chapter; Making decisions using NICE guidelines; NICE terms and conditions, including the Notice of Rights

  4. Recommended Blood-pressure lowering to a target

    Issued by: National Institute for Health and Care Excellence · Where: Not stated · Strength: Not labeled on the fetched page. The recommendation uses imperative wording (directive verbs to lower the pressure and to keep it there).

    Sources: Hypertension in adults: diagnosis and management (NICE guideline NG136), Recommendations chapter; Making decisions using NICE guidelines

  5. Recommended against Salt substitution (lower-sodium, potassium-containing salt)

    Issued by: National Institute for Health and Care Excellence · Where: GB-ENG (United Kingdom) · Strength: Not labeled on the fetched page. The caution uses the wording should not be used.

    Sources: Hypertension in adults: diagnosis and management (NICE guideline NG136), Recommendations chapter; NICE terms and conditions, including the Notice of Rights

  6. Study start TRILUMINATE Pivotal trial

    Source: TRILUMINATE Pivotal Trial

  7. Supplemental approval CoreValve and Evolut transcatheter valves

    Authority: U.S. Food and Drug Administration · Pathway: PMA · Submission: P130021/S058 · Where: United States

    Sources: FDA premarket approval record P130021/S058: Medtronic CoreValve Evolut R and Evolut PRO systems (PMA supplement S058, low-risk indication) (openFDA record); FDA approval order for PMA supplement P130021/S058 (CoreValve Evolut R and Evolut PRO, low-risk indication)

  8. Supplemental approval SAPIEN 3 transcatheter heart valve

    Authority: U.S. Food and Drug Administration · Pathway: PMA · Submission: P140031/S085 · Where: United States

    Sources: FDA premarket approval record P140031/S085: SAPIEN 3 and SAPIEN 3 Ultra transcatheter heart valves (PMA supplement S085, low-risk indication) (openFDA record); FDA approval order for PMA supplement P140031/S085 (SAPIEN 3 and SAPIEN 3 Ultra, low-risk indication)

  9. Study completion DAPA-HF

    Source: Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure

  10. Primary completion DAPA-HF

    Source: Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure

  11. Primary completion ISCHEMIA (initial invasive or conservative strategy for stable coronary disease)

    Source: International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)

  12. Study start FLOW: semaglutide and kidney outcomes in type 2 diabetes with chronic kidney disease

    Source: A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

  13. Approval HeartStart OnSite and Home defibrillators

    Authority: U.S. Food and Drug Administration · Pathway: PMA · Submission: P160029 · Where: United States

    Sources: FDA premarket approval P160029: HeartStart OnSite and HeartStart Home defibrillators (openFDA record of the original approval); FDA approval order for PMA P160029 (HeartStart OnSite and Home defibrillators); FDA summary of safety and effectiveness data for PMA P160029 (HeartStart OnSite and Home defibrillators)

  14. Results first posted ODYSSEY OUTCOMES (alirocumab after acute coronary syndrome)

    Source: ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

  15. Edition published 2019 ACC/AHA guideline on the primary prevention of CVD

    Issued jointly by: American College of Cardiology, American Heart Association · Edition: 2019 guideline

    Source: 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

  16. Supplemental approval MitraClip

    Authority: U.S. Food and Drug Administration · Pathway: PMA · Submission: P100009/S028 · Where: United States

    Sources: FDA premarket approval record P100009/S028: MitraClip NT and NTR/XTR Clip Delivery Systems (PMA supplement S028, secondary mitral regurgitation) (openFDA record); FDA approval order for PMA supplement P100009/S028 (MitraClip, secondary mitral regurgitation)

  17. Primary completion COAPT trial

    Source: Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation (The COAPT Trial) and COAPT CAS

  18. Study completion Systolic Blood Pressure Intervention Trial (SPRINT)

    Source: Systolic Blood Pressure Intervention Trial (SPRINT)

  19. Study completion Apple Heart Study

    Source: Apple Heart Study: Assessment of Wristwatch-Based Photoplethysmography to Identify Cardiac Arrhythmias

  20. Primary completion Apple Heart Study

    Source: Apple Heart Study: Assessment of Wristwatch-Based Photoplethysmography to Identify Cardiac Arrhythmias

  21. Study start EMPA-KIDNEY: empagliflozin in a broad range of chronic kidney disease

    Source: EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

2018 9

  1. Study start ORION-4 (inclisiran outcome trial)

    Source: A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease

  2. Study start SELECT: semaglutide and cardiovascular outcomes in overweight or obesity

    Source: Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

  3. Study completion DECLARE-TIMI 58: dapagliflozin and cardiovascular outcomes in type 2 diabetes

    Source: Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events

  4. Primary completion DECLARE-TIMI 58: dapagliflozin and cardiovascular outcomes in type 2 diabetes

    Source: Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events

  5. Granted Irregular Rhythm Notification Feature (Apple)

    Authority: U.S. Food and Drug Administration · Pathway: De Novo · Submission: DEN180042 · Where: United States

    Sources: FDA De Novo DEN180042: Irregular Rhythm Notification Feature (openFDA record); FDA Device Classification Under Section 513(f)(2) (De Novo): DEN180042, Irregular Rhythm Notification Feature

  6. Study start DELIVER

    Source: Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.

  7. Results first posted FOURIER (evolocumab in people with cardiovascular disease)

    Source: Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

  8. Study completion ODYSSEY OUTCOMES (alirocumab after acute coronary syndrome)

    Source: ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

  9. Primary completion ODYSSEY OUTCOMES (alirocumab after acute coronary syndrome)

    Source: ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

2017 11

  1. Approval Semaglutide injection for diabetes (Ozempic)

    Authority: U.S. Food and Drug Administration · Pathway: NDA · Submission: NDA209637 · Where: United States

    Sources: FDA New Drug Application NDA209637: Ozempic (openFDA drugsfda record); Drugs@FDA: approval date(s) and history for NDA 209637 (Ozempic); Ozempic drug label (openFDA record, set id 42bdd912-2393-44c4-b7e0-47672ca28991)

  2. Study start Apple Heart Study

    Source: Apple Heart Study: Assessment of Wristwatch-Based Photoplethysmography to Identify Cardiac Arrhythmias

  3. Study start TTM2

    Source: Targeted Hypothermia Versus Targeted Normothermia After Out-of-hospital Cardiac Arrest

  4. Study start EARLY TAVR

    Source: EARLY TAVR: Evaluation of TAVR Compared to Surveillance for Patients With Asymptomatic Severe Aortic Stenosis

  5. Study start EMPEROR-Reduced

    Source: EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)

  6. Study start EMPEROR-Preserved

    Source: EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)

  7. Results first posted LEADER: liraglutide and cardiovascular events in type 2 diabetes

    Source: Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results

  8. Supplemental approval Melody transcatheter pulmonary valve

    Authority: U.S. Food and Drug Administration · Pathway: PMA · Submission: P140017/S005 · Where: United States

    Sources: FDA premarket approval record P140017/S005: Melody Transcatheter Pulmonary Valve (PMA supplement S005, surgical bioprosthetic pulmonary valve) (openFDA record); FDA approval order for PMA supplement P140017/S005 (Melody valve, surgical bioprosthetic pulmonary valve)

  9. Study start DAPA-HF

    Source: Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure

  10. Study start DAPA-CKD: dapagliflozin in chronic kidney disease

    Source: A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease

  11. Clearance Elecsys Troponin T Gen 5 STAT assay

    Authority: U.S. Food and Drug Administration · Pathway: 510(k) · Submission: K162895 · Where: United States

    Sources: FDA 510(k) premarket notification K162895: Elecsys Troponin T Gen 5 STAT Assay and related calibrator and control materials (openFDA record); FDA 510(k) substantial equivalence determination decision summary for K162895 (Elecsys Troponin T Gen 5 STAT)

2016 9

  1. Study start CLEAR Outcomes (bempedoic acid in statin-intolerant people)

    Source: Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo

  2. Study completion FOURIER (evolocumab in people with cardiovascular disease)

    Source: Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

  3. Primary completion FOURIER (evolocumab in people with cardiovascular disease)

    Source: Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

  4. Study start SECURE Registry does not say if reached

    Source: Secondary Prevention of Cardiovascular Disease in the Elderly Trial

  5. Primary completion Systolic Blood Pressure Intervention Trial (SPRINT)

    Source: Systolic Blood Pressure Intervention Trial (SPRINT)

  6. Study completion DANISH

    Source: Danish ICD Study in Patients With Dilated Cardiomyopathy

  7. Primary completion DANISH

    Source: Danish ICD Study in Patients With Dilated Cardiomyopathy

  8. Study start Evolut Low Risk trial Registry does not say if reached

    Source: Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk Patients

  9. Study start PARTNER 3 trial

    Source: PARTNER 3 Trial: Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis

2015 14

  1. Study completion LEADER: liraglutide and cardiovascular events in type 2 diabetes

    Source: Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results

  2. Primary completion LEADER: liraglutide and cardiovascular events in type 2 diabetes

    Source: Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results

  3. Results first posted IMPROVE-IT (ezetimibe added to simvastatin after acute coronary syndrome) Registry does not say if reached

    Source: IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103)

  4. Study start FIDELIO-DKD: finerenone and kidney outcomes in type 2 diabetes

    Source: Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease

  5. Results first posted PARADIGM-HF Registry does not say if reached

    Source: This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure

  6. Approval Evolocumab (Repatha)

    Authority: U.S. Food and Drug Administration · Pathway: BLA · Submission: BLA125522 · Where: United States

    Sources: Drugs@FDA application BLA125522: REPATHA (evolocumab) (openFDA drugsfda record); Drugs@FDA overview page for BLA125522; REPATHA drug label (openFDA record, set id cd61e902-166d-4aa6-9f3c-a18c1008d07e)

  7. Stopped early Systolic Blood Pressure Intervention Trial (SPRINT)

    What stopped: intervention

    Source: A Randomized Trial of Intensive versus Standard Blood-Pressure Control

  8. Approval Sacubitril/valsartan (Entresto)

    Authority: U.S. Food and Drug Administration · Pathway: NDA · Submission: NDA207620 · Where: United States

    Sources: openFDA Drugs@FDA record for NDA207620: ENTRESTO (sacubitril and valsartan tablets); Drugs@FDA overview page for NDA 207620 (ENTRESTO)

  9. Approval SAPIEN 3 transcatheter heart valve

    Authority: U.S. Food and Drug Administration · Pathway: PMA · Submission: P140031 · Where: United States

    Sources: FDA premarket approval record P140031: Edwards SAPIEN 3 transcatheter heart valve (original PMA approval) (openFDA record); FDA summary of safety and effectiveness data for PMA P140031 (SAPIEN 3)

  10. Results first posted PROTECT AF Registry does not say if reached

    Source: WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation (PROTECT AF)

  11. Study completion EMPA-REG OUTCOME: empagliflozin and cardiovascular outcomes in type 2 diabetes

    Source: BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).

  12. Primary completion EMPA-REG OUTCOME: empagliflozin and cardiovascular outcomes in type 2 diabetes

    Source: BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).

  13. Approval WATCHMAN left atrial appendage closure device

    Authority: U.S. Food and Drug Administration · Pathway: PMA · Submission: P130013 · Where: United States

    Source: FDA premarket approval P130013: WATCHMAN LEFT ATRIAL APPENDAGE (LAA) CLOSURE TECHNOLOGY (openFDA record of the original approval)

  14. Approval Melody transcatheter pulmonary valve

    Authority: U.S. Food and Drug Administration · Pathway: PMA · Submission: P140017 · Where: United States

    Sources: FDA premarket approval record P140017: Melody Transcatheter Pulmonary Valve and Ensemble delivery system (original PMA approval) (openFDA record); FDA summary of safety and effectiveness data for PMA P140017 (Melody valve)

2014 11

  1. Study completion CHAMPION trial

    Source: CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients

  2. Study completion IMPROVE-IT (ezetimibe added to simvastatin after acute coronary syndrome)

    Source: IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103)

  3. Primary completion IMPROVE-IT (ezetimibe added to simvastatin after acute coronary syndrome)

    Source: IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103)

  4. Approval Empagliflozin (Jardiance)

    Authority: U.S. Food and Drug Administration · Pathway: NDA · Submission: NDA204629 · Where: United States

    Sources: openFDA Drugs@FDA record for NDA204629: JARDIANCE (empagliflozin tablets); Drugs@FDA overview page for NDA 204629 (JARDIANCE)

  5. Study start China Salt Substitute and Stroke Study (SSaSS)

    Source: China Salt Substitute and Stroke Study

  6. Approval CardioMEMS HF System

    Authority: U.S. Food and Drug Administration · Pathway: PMA · Submission: P100045 · Where: United States

    Source: openFDA premarket approval (PMA) records for P100045: CardioMEMS HF Pressure Measurement System

  7. Study completion PARADIGM-HF

    Source: This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure

  8. Primary completion PARADIGM-HF

    Source: This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure

  9. Study completion PROTECT AF

    Source: WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation (PROTECT AF)

  10. Approval CoreValve and Evolut transcatheter valves

    Authority: U.S. Food and Drug Administration · Pathway: PMA · Submission: P130021 · Where: United States

    Sources: FDA premarket approval record P130021: Medtronic CoreValve System (original PMA approval) (openFDA record); FDA summary of safety and effectiveness data for PMA P130021 (CoreValve)

  11. Approval Dapagliflozin (Farxiga)

    Authority: U.S. Food and Drug Administration · Pathway: NDA · Submission: NDA202293 · Where: United States

    Sources: openFDA Drugs@FDA record for NDA202293: FARXIGA (dapagliflozin tablets); Drugs@FDA overview page for NDA 202293 (FARXIGA)

2013 6

  1. Approval MitraClip

    Authority: U.S. Food and Drug Administration · Pathway: PMA · Submission: P100009 · Where: United States

    Source: FDA premarket approval record P100009: MitraClip Clip Delivery System (original PMA approval) (openFDA record)

  2. Primary completion PROTECT AF

    Source: WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation (PROTECT AF)

  3. Results first posted ARISTOTLE Registry does not say if reached

    Source: Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation (ARISTOTLE)

  4. Study start DECLARE-TIMI 58: dapagliflozin and cardiovascular outcomes in type 2 diabetes

    Source: Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events

  5. Results first posted CHAMPION trial Registry does not say if reached

    Source: CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients

  6. Study start FOURIER (evolocumab in people with cardiovascular disease)

    Source: Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

2012 7

  1. Approval Apixaban (Eliquis)

    Authority: U.S. Food and Drug Administration · Pathway: NDA · Submission: NDA202155 · Where: United States

    Sources: FDA drug application NDA202155 (openFDA Drugs@FDA record); FDA approval letter for NDA NDA202155

  2. Study start ODYSSEY OUTCOMES (alirocumab after acute coronary syndrome)

    Source: ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

  3. Approval Subcutaneous ICD (S-ICD) system

    Authority: U.S. Food and Drug Administration · Pathway: PMA · Submission: P110042 · Where: United States

    Sources: FDA premarket approval P110042: subcutaneous implantable defibrillator (S-ICD) system (openFDA record of the original approval); FDA approval order for PMA P110042 (subcutaneous implantable defibrillator system, 28 September 2012); FDA summary of safety and effectiveness data for PMA P110042 (S-ICD system)

  4. Primary completion Look AHEAD: intensive lifestyle intervention in type 2 diabetes

    Source: Look AHEAD: Action for Health in Diabetes

  5. Study start COAPT trial

    Source: Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation (The COAPT Trial) and COAPT CAS

  6. Results first posted ROCKET AF Registry does not say if reached

    Source: An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation (ROCKET AF)

  7. Study start ISCHEMIA (initial invasive or conservative strategy for stable coronary disease) Registry does not say if reached

    Source: International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)

2011 4

  1. Approval Rivaroxaban (Xarelto)

    Authority: U.S. Food and Drug Administration · Pathway: NDA · Submission: NDA202439 · Where: United States

    Sources: FDA drug application NDA202439 (openFDA Drugs@FDA record); FDA approval letter for NDA NDA202439; FDA drug application NDA022406 (openFDA Drugs@FDA record); FDA approval letter for NDA NDA022406

  2. Study completion ARISTOTLE

    Source: Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation (ARISTOTLE)

  3. Primary completion ARISTOTLE

    Source: Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation (ARISTOTLE)

  4. Results first posted RE-LY Registry does not say if reached

    Source: Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate

2010 7

  1. Approval Dabigatran (Pradaxa)

    Authority: U.S. Food and Drug Administration · Pathway: NDA · Submission: NDA022512 · Where: United States

    Sources: FDA drug application NDA022512 (openFDA Drugs@FDA record); FDA approval letter for NDA NDA022512

  2. Study start Systolic Blood Pressure Intervention Trial (SPRINT)

    Source: Systolic Blood Pressure Intervention Trial (SPRINT)

  3. Study completion ROCKET AF

    Source: An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation (ROCKET AF)

  4. Primary completion ROCKET AF

    Source: An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation (ROCKET AF)

  5. Study start LEADER: liraglutide and cardiovascular events in type 2 diabetes

    Source: Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results

  6. Study start EMPA-REG OUTCOME: empagliflozin and cardiovascular outcomes in type 2 diabetes Registry does not say if reached

    Source: BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).

  7. Primary completion CHAMPION trial

    Source: CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients

2009 2

  1. Study start PARADIGM-HF Registry does not say if reached

    Source: This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure

  2. Primary completion RE-LY

    Source: Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate

2008 3

  1. Study completion HF-ACTION

    Source: Exercise Training Program to Improve Clinical Outcomes in Individuals With Congestive Heart Failure

  2. Primary completion HF-ACTION

    Source: Exercise Training Program to Improve Clinical Outcomes in Individuals With Congestive Heart Failure

  3. Study start DANISH

    Source: Danish ICD Study in Patients With Dilated Cardiomyopathy

2007 1

  1. Study start CHAMPION trial Registry does not say if reached

    Source: CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients

2006 2

  1. Study start ARISTOTLE

    Source: Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation (ARISTOTLE)

  2. Study start ROCKET AF Registry does not say if reached

    Source: An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation (ROCKET AF)

2005 4

  1. Study start RE-LY

    Source: Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate

  2. Study start IMPROVE-IT (ezetimibe added to simvastatin after acute coronary syndrome)

    Source: IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103)

  3. Study completion SCD-HeFT

    Source: Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)

  4. Study start PROTECT AF Registry does not say if reached

    Source: WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation (PROTECT AF)

2003 1

  1. Study start HF-ACTION Registry does not say if reached

    Source: Exercise Training Program to Improve Clinical Outcomes in Individuals With Congestive Heart Failure

2002 2

  1. Study completion DASH-Sodium

    Source: Dietary Patterns, Sodium Intake and Blood Pressure (DASH - Sodium)

  2. Primary completion DASH-Sodium

    Source: Dietary Patterns, Sodium Intake and Blood Pressure (DASH - Sodium)

2001 2

  1. Approval Amplatzer Septal Occluder

    Authority: U.S. Food and Drug Administration · Pathway: PMA · Submission: P000039 · Where: United States

    Source: FDA premarket approval record P000039: Amplatzer Septal Occluder and Exchange System (original PMA approval) (openFDA record)

  2. Study start Look AHEAD: intensive lifestyle intervention in type 2 diabetes

    Source: Look AHEAD: Action for Health in Diabetes

2000 1

  1. Clearance Omron HEM-907 blood pressure monitor

    Authority: U.S. Food and Drug Administration · Pathway: 510(k) · Submission: K001848 · Where: United States

    Source: FDA 510(k) premarket notification K001848: OMRON INTELLISENSE BLOOD PRESSURE MONITOR, MODEL HEM-907 (openFDA record)

1997 2

  1. Study start SCD-HeFT Registry does not say if reached

    Source: Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)

  2. Study start DASH-Sodium Registry does not say if reached

    Source: Dietary Patterns, Sodium Intake and Blood Pressure (DASH - Sodium)